Boston Trust Walden Corp Has $82.91 Million Holdings in The Cooper Companies, Inc. $COO

Boston Trust Walden Corp lessened its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 6.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,159,562 shares of the medical device company’s stock after selling 77,917 shares during the quarter. Boston Trust Walden Corp owned about 0.59% of Cooper Companies worth $82,909,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Root Financial Partners LLC raised its position in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares during the period. SJS Investment Consulting Inc. grew its holdings in Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the period. Bell Investment Advisors Inc increased its stake in Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares in the last quarter. True Wealth Design LLC increased its stake in Cooper Companies by 484.8% in the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 383 shares in the last quarter. Finally, Cromwell Holdings LLC raised its holdings in Cooper Companies by 128.8% in the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock worth $40,000 after purchasing an additional 273 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Trading Up 3.1%

COO opened at $74.20 on Friday. The stock has a market capitalization of $14.47 billion, a P/E ratio of 62.88, a P/E/G ratio of 1.88 and a beta of 0.84. The Cooper Companies, Inc. has a 12 month low of $58.89 and a 12 month high of $89.83. The firm’s fifty day simple moving average is $64.36 and its 200 day simple moving average is $73.37. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on COO. Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Sunday, June 21st. Piper Sandler set a $86.00 price objective on shares of Cooper Companies and gave the company an “overweight” rating in a research report on Monday, June 1st. JPMorgan Chase & Co. dropped their price objective on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research note on Friday, June 5th. Robert W. Baird reduced their target price on Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Finally, Wells Fargo & Company reissued a “sell” rating and issued a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research note on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Cooper Companies presently has an average rating of “Hold” and an average target price of $81.31.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.